Emergent Piotroski F Score


USD 31.65  1.09  3.33%   

This module uses fundamental data of Emergent Biosolutions to approximate its Piotroski F score. Emergent Biosolutions F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Emergent Biosolutions. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Emergent Biosolutions financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Continue to Emergent Biosolutions Altman Z Score, Emergent Biosolutions Correlation, Emergent Biosolutions Valuation, as well as analyze Emergent Biosolutions Alpha and Beta and Emergent Biosolutions Hype Analysis.
As of 08/07/2022, Total Debt is likely to drop to about 668.2 M. In addition to that, Debt Current is likely to drop to about 26.4 M. Emergent Biosolutions Net Current Assets as percentage of Total Assets are relatively stable at the moment as compared to the past year. Emergent Biosolutions reported last year Net Current Assets as percentage of Total Assets of 30.36. As of 08/07/2022, Asset Turnover is likely to grow to 0.63, while PPandE Turnover is likely to drop 2.04.
At this time, it appears that Emergent Biosolutions' Piotroski F Score is Strong. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
Piotroski F Score - Strong
Current Return On AssetsPositiveFocus
Change in Return on AssetsDecreasedFocus
Cash Flow Return on AssetsPositiveFocus
Current Quality of Earnings (accrual)ImprovingFocus
Asset Turnover GrowthIncreaseFocus
Current Ratio ChangeIncreaseFocus
Long Term Debt Over Assets ChangeLower LeverageFocus
Change In Outstending SharesDecreaseFocus
Change in Gross MarginIncreaseFocus

Emergent Biosolutions Piotroski F Score Drivers

The critical factor to consider when applying the Piotroski F Score to Emergent Biosolutions is to make sure Emergent is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Emergent Biosolutions' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Emergent Biosolutions' financial numbers are properly reported.
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares53.1 M53.5 M
Slightly Down
Slightly volatile
Weighted Average Shares Diluted55.5 M54.1 M
Fairly Up
Slightly volatile
Net Cash Flow from Operations256 M321.1 M
Significantly Down
Slightly volatile
Total Assets2.4 BB
Significantly Down
Slightly volatile
Total Liabilities1.1 B1.3 B
Significantly Down
Slightly volatile
Current AssetsB1.3 B
Significantly Down
Slightly volatile
Current Liabilities403.3 M373.8 M
Significantly Up
Slightly volatile
Total Debt668.2 M841 M
Significantly Down
Slightly volatile
Return on Average Assets0.07580.079
Sufficiently Down
Slightly volatile
Gross Margin0.60.577
Sufficiently Up
Slightly volatile
Asset Turnover0.630.616
Fairly Up
Slightly volatile

Emergent Biosolutions F Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Emergent Biosolutions' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Emergent Biosolutions in a much-optimized way.

About Emergent Biosolutions Piotroski F Score

F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.

Weighted Average Shares

53.09 Million

Emergent Biosolutions Weighted Average Shares is relatively stable at the moment as compared to the past year. Emergent Biosolutions reported last year Weighted Average Shares of 53.5 Million

Emergent Biosolutions Current Valuation Drivers

We derive many important indicators used in calculating different scores of Emergent Biosolutions from analyzing Emergent Biosolutions' financial statements. These drivers represent accounts that assess Emergent Biosolutions' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Emergent Biosolutions' important valuation drivers and their relationship over time.
201720182019202020212022 (projected)
Net Income Per Employee65.76 K36.77 K29.72 K434.67 K95.57 K83.02 K
Revenue Per Employee446.56 K458.89 K603.05 K2.22 M742.01 K633.64 K
Average Assets1 B1.4 B2.28 B2.56 B2.91 B2.3 B
Earnings Before Interest Taxes and Depreciation Amortization EBITDA167.8 M153.6 M226.5 M553 M472.7 M510.02 M
Earnings Before Interest Taxes and Depreciation Amortization USD167.8 M153.6 M226.5 M553 M472.7 M510.02 M
Earnings before Tax118.6 M81.5 M77.4 M407.2 M314.4 M339.22 M
Average Equity701.76 M949.29 M1.02 B1.24 B1.55 B1.26 B
Enterprise Value1.83 B2.69 B3.47 B5.21 B2.78 B2.6 B
Free Cash Flow153.3 M(30.3 M)101.1 M395 M96.1 M91.2 M
Invested Capital635.6 M1.69 B1.77 B1.82 B2.02 B1.67 B
Invested Capital Average742.21 M911.65 M1.67 B1.77 B2.01 B1.61 B
Market Capitalization1.92 B3.02 B2.79 B4.75 B2.34 B2.32 B
Tangible Asset Value901.5 M1.21 B1.35 B1.95 B2.13 B1.75 B
Working Capital385.3 M420.4 M469.9 M811.4 M898.3 M723.74 M

About Emergent Biosolutions Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Emergent Biosolutions's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Emergent Biosolutions using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Emergent Biosolutions based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats in the United States. The companys products address PHTs, which include chemical, biological, radiological, nuclear, and explosives emerging infectious diseases travel health and emerging health crises and acuteemergency care. It offers BioThrax, an anthrax vaccine ACAM2000, a smallpox vaccine Botulism Antitoxin Heptavalent to treat botulinum disease vaccinia immune globulin intravenous that addresses complications from smallpox vaccine raxibacumab for the treatment and prophylaxis of inhalational anthrax Anthrasil to for inhalational anthrax reactive skin decontamination lotion kits and Trobigard, a combination drug-device auto injector product candidate and Trobigard, a combination drug-device auto injector product candidate. The company also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose Vivotif, an oral vaccine for typhoid fever and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, it is developing AP003, a Naloxone multidose nasal spray AP007, a sustained release Nalmefene injection for treatment of opioid use disorder AV7909, an anthrax vaccine CGRD-001, a pralidoxime chlorideatropine auto-injector CHIKV VLP, a chikungunya virus VLP vaccine COVID-HIG for the treatment of SARS-CoV2 EGRD-001, a diazepam auto-injector SIAN, an antidote for the initial treatment of acute poisoning of cyanide and UniFlu, a universal influenza vaccine. Further, the company provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Emergent Biosolutions without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Focused Opportunities Now


Focused Opportunities

Build portfolios using our predefined set of ideas and optimize them against your investing preferences
All  Next Launch Module

Pair Trading with Emergent Biosolutions

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Emergent Biosolutions position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Emergent Biosolutions will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Emergent Biosolutions could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Emergent Biosolutions when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Emergent Biosolutions - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Emergent Biosolutions to buy it.
The correlation of Emergent Biosolutions is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Emergent Biosolutions moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Emergent Biosolutions moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Emergent Biosolutions can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to Emergent Biosolutions Altman Z Score, Emergent Biosolutions Correlation, Emergent Biosolutions Valuation, as well as analyze Emergent Biosolutions Alpha and Beta and Emergent Biosolutions Hype Analysis. Note that the Emergent Biosolutions information on this page should be used as a complementary analysis to other Emergent Biosolutions' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Analyst Recommendations module to analyst recommendations and target price estimates broken down by several categories.

Complementary Tools for Emergent Stock analysis

When running Emergent Biosolutions price analysis, check to measure Emergent Biosolutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Emergent Biosolutions is operating at the current time. Most of Emergent Biosolutions' value examination focuses on studying past and present price action to predict the probability of Emergent Biosolutions' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Emergent Biosolutions' price. Additionally, you may evaluate how the addition of Emergent Biosolutions to your portfolios can decrease your overall portfolio volatility.
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Is Emergent Biosolutions' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Emergent Biosolutions. If investors know Emergent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Emergent Biosolutions listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
Market Capitalization
1.6 B
Quarterly Revenue Growth YOY
Return On Assets
Return On Equity
The market value of Emergent Biosolutions is measured differently than its book value, which is the value of Emergent that is recorded on the company's balance sheet. Investors also form their own opinion of Emergent Biosolutions' value that differs from its market value or its book value, called intrinsic value, which is Emergent Biosolutions' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Emergent Biosolutions' market value can be influenced by many factors that don't directly affect Emergent Biosolutions' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Emergent Biosolutions' value and its price as these two are different measures arrived at by different means. Investors typically determine Emergent Biosolutions value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Emergent Biosolutions' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.